Literature DB >> 16874886

Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database.

Margarida Julià-Sapé1, Dionisio Acosta, Carles Majós, Angel Moreno-Torres, Pieter Wesseling, Juan José Acebes, John R Griffiths, Carles Arús.   

Abstract

OBJECT: The aim of this study was to estimate the accuracy of routine magnetic resonance (MR) imaging studies in the classification of brain tumors in terms of both cell type and grade of malignancy.
METHODS: The authors retrospectively assessed the correlation between neuroimaging classifications and histopathological diagnoses by using multicenter database records from 393 patients with brain tumors. An ontology was devised to establish diagnostic agreement. Each tumor category was compared with the corresponding histopathological diagnoses by dichotomization. Sensitivity, specificity, positive and negative predictive values (PPVs and NPVs, respectively), and the Wilson 95% confidence intervals (CI) for each were calculated. In routine reporting of MR imaging examinations, tumor types and grades were classified with a high specificity (85.2-100%); sensitivity varied, depending on the tumor type and grade, alone or in combination. The recognition of broad diagnostic categories (neuroepithelial or meningeal lesions) was highly sensitive, whereas when both detailed type and grade were considered, sensitivity diverged, being highest in low-grade meningioma (sensitivity 100%, 95% CI 96.2-100.0%) and lowest in high-grade meningioma (sensitivity 0.0%, 95% CI 0.0-65.8%) and low-grade oligodendroglioma (sensitivity 15%, 95% CI 5.2-36.0%). In neuroepithelial tumors, sensitivity was inversely related to the precision in reporting of grade and cellular origin; "glioma" was a frequent neuroimaging classification associated with higher sensitivity in the corresponding category. The PPVs varied among categories, in general being greater than their prevalence in this dataset. The NPV was high in all categories (69.8-100%).
CONCLUSIONS: The PPVs and NPVs provided in this study may be used as estimates of posttest probabilities of diagnostic accuracy using MR imaging. This study targets the need for noninvasively increasing sensitivity in categorizing most brain tumor types while retaining high specificity, especially in the differentiation of high- and low-grade glial tumor classes.

Entities:  

Mesh:

Year:  2006        PMID: 16874886     DOI: 10.3171/jns.2006.105.1.6

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Molecular classification of brain tumor biopsies using solid-state magic angle spinning proton magnetic resonance spectroscopy and robust classifiers.

Authors:  Ovidiu C Andronesi; Konstantinos D Blekas; Dionyssios Mintzopoulos; Loukas Astrakas; Peter M Black; A Aria Tzika
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

2.  SpectraClassifier 1.0: a user friendly, automated MRS-based classifier-development system.

Authors:  Sandra Ortega-Martorell; Iván Olier; Margarida Julià-Sapé; Carles Arús
Journal:  BMC Bioinformatics       Date:  2010-02-24       Impact factor: 3.169

3.  The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses.

Authors:  Alexander Pérez-Ruiz; Margarida Julià-Sapé; Guillem Mercadal; Iván Olier; Carles Majós; Carles Arús
Journal:  BMC Bioinformatics       Date:  2010-11-29       Impact factor: 3.169

4.  Possible role of single-voxel (1)H-MRS in differential diagnosis of suprasellar tumors.

Authors:  Mikhail F Chernov; Takakazu Kawamata; Kosaku Amano; Yuko Ono; Takashi Suzuki; Ryoichi Nakamura; Yoshihiro Muragaki; Hiroshi Iseki; Osami Kubo; Tomokatsu Hori; Kintomo Takakura
Journal:  J Neurooncol       Date:  2008-09-30       Impact factor: 4.130

5.  Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas.

Authors:  Remy Guillevin; Carole Menuel; Hugues Duffau; Michel Kujas; Laurent Capelle; Agnès Aubert; Sophie Taillibert; Ahmed Idbaih; Joan Pallud; Giovanni Demarco; Robert Costalat; Khê Hoang-Xuan; Jacques Chiras; Jean-Noel Vallée
Journal:  J Neurooncol       Date:  2007-12-28       Impact factor: 4.130

6.  Clinical Relevance of Single-Voxel (1)H MRS Metabolites in Discriminating Suprasellar Tumors.

Authors:  A Einstien; Rahul A Virani
Journal:  J Clin Diagn Res       Date:  2016-07-01

7.  Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.

Authors:  R Guillevin; C Menuel; S Taillibert; L Capelle; R Costalat; L Abud; C Habas; G De Marco; K Hoang-Xuan; J Chiras; J-N Vallée
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

8.  Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy.

Authors:  Juan M García-Gómez; Jan Luts; Margarida Julià-Sapé; Patrick Krooshof; Salvador Tortajada; Javier Vicente Robledo; Willem Melssen; Elies Fuster-García; Iván Olier; Geert Postma; Daniel Monleón; Angel Moreno-Torres; Jesús Pujol; Ana-Paula Candiota; M Carmen Martínez-Bisbal; Johan Suykens; Lutgarde Buydens; Bernardo Celda; Sabine Van Huffel; Carles Arús; Montserrat Robles
Journal:  MAGMA       Date:  2008-11-07       Impact factor: 2.310

9.  Strategies for annotation and curation of translational databases: the eTUMOUR project.

Authors:  Margarida Julià-Sapé; Miguel Lurgi; Mariola Mier; Francesc Estanyol; Xavier Rafael; Ana Paula Candiota; Anna Barceló; Alina García; M Carmen Martínez-Bisbal; Rubén Ferrer-Luna; Ángel Moreno-Torres; Bernardo Celda; Carles Arús
Journal:  Database (Oxford)       Date:  2012-11-22       Impact factor: 3.451

10.  A novel semi-supervised methodology for extracting tumor type-specific MRS sources in human brain data.

Authors:  Sandra Ortega-Martorell; Héctor Ruiz; Alfredo Vellido; Iván Olier; Enrique Romero; Margarida Julià-Sapé; José D Martín; Ian H Jarman; Carles Arús; Paulo J G Lisboa
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.